Daniel A Walz

Title: The Innovations of Daniel A. Walz

Introduction

Daniel A. Walz is a notable inventor based in Detroit, MI, who has made significant contributions to the field of medical research. He holds two patents that focus on critical methods for measuring blood procoagulant activity and testing for metastatic tumor cells. His work has implications for cancer treatment and understanding tumor metastasis.

Latest Patents

Walz's latest patents include a "Method for measuring blood procoagulant activity of human leukocyte" and a "Method for testing for the presence of metastatic tumor cells." The first patent addresses thromboembolic complications in cancer patients and mismatched organ transplant recipients. It identifies two proteins with procoagulant activity isolated from human ovarian carcinoma extracts. The amino terminal sequence of one of these proteins shows 100% homology to the major histocompatibility antigen HLA-DR. The second patent describes a method for detecting metastatic tumor cells based on the presence of Human Leukocyte Antigen (HLA), utilizing a protein that selectively binds to HLA.

Career Highlights

Walz is associated with Biomide Investment Limited Partnership, where he continues to innovate in the medical field. His research has the potential to enhance the understanding of cancer biology and improve diagnostic methods.

Collaborations

Some of his notable coworkers include Mohanathasan Chelladurai and Kenneth V. Honn, who have contributed to his research endeavors.

Conclusion

Daniel A. Walz's work exemplifies the intersection of innovation and medical research, with patents that could significantly impact cancer diagnostics and treatment. His contributions are vital in advancing our understanding of complex medical conditions.